Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Views

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>

27 March 2014: Letters to the Editor - 17/03 - Science startups, Best of Twitter

[Re: Why Britain’s scientists are failing at business, Friday]
Tim Farron is right to highlight some of the challenges facing all entrepreneurs in this country, but the idea that Britain’s scientific community is failing at business is simply not accurate.
More...

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>